Chanal J, et al. - Researchers assessed 9 individuals of age more than 85 years to analyze the tolerance and possible advantages of pembrolizu­mab [programmed cell death protein-1 (PD-1) inhibitors] for unresectable or metastatic melanoma, between January 2015 and January 2018. They recorded the mean number of infusions, 4 (1–12). They noticed that most cases were unable to tolerate the 4-infusion schedule. About 7 candidates were observed with grade 3 or 4 treatment-related adverse experiences. Hence, they concluded that its use induced responses but were concomitant to a high risk of toxicity and impaired autonomy.